PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5506
- Registration Number
- NCT05520138
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 659
- Registration Number
- NCT05518123
- Locations
- 🇸🇪
University Hospital Uppsala (VO Neuro), Uppsala, Sweden
🇧🇪GZA Ziekenhuizen, Antwerpen, Belgium
🇧🇪AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 401
- Registration Number
- NCT05512819
- Locations
- 🇮🇳
Maulana Azad Medical College and Associated with Lok Nayak Hospital, New Delhi, Delhi, India
🇮🇳Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳BGS Global Institute of Medical Sciences (BGSGIMS), Bangalore, Karnataka, India
Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 565
- Registration Number
- NCT05509894
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 633
- Registration Number
- NCT05509400
- Locations
- 🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇬🇧4 Medical Clinical Solutions, Swinton, United Kingdom
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05510245
- Locations
- 🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
- Conditions
- Breast CancerBreast Carcinoma
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT05505175
- Locations
- 🇧🇷
NOB - Nucleo de Oncologia da Bahia, Salvador, Bahia, Brazil
🇧🇷Oncoclínicas Do Brasil Servicos Médicos S/A - Oncocentro, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Ensino E Terapia de Inovação Clínica Amo - Ética, Salvador, Bahia, Brazil
A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT05498701
- Locations
- 🇨🇦
Pharma Medica Research Inc, Toronto, Ontario, Canada
A Preliminary Study to Evaluate PF-07264660 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: PF-07264660 subcutaneous multiple ascending doseOther: Intravenous placeboDrug: PF-07264660 intravenous single ascending doseOther: subcutaneous placebo
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT05496738
- Locations
- 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Spaulding Clinical Research, West Bend, Wisconsin, United States
🇺🇸Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
A Study of Ponsegromab in People With Heart Failure
- Conditions
- Heart Failure
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 456
- Registration Number
- NCT05492500
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
🇨🇿Ustredni vojenska nemocnice, Praha 6, Czechia
🇩🇪Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, Hessen, Germany